NASDAQ:EVLO Evelo Biosciences Earnings Date & Estimates Evelo Biosciences is estimated to report earnings on Tuesday, November 17, 2026. Research:Profile Upcoming Earnings Announcement Announcement DateNovember 17, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Evelo BiosciencesEvelo Biosciences is expected to post earnings of -$10.1333 per share. Evelo Biosciences last reported on November 9, 2023, posting -$0.66 per share and beating the -$1.34 consensus estimate. Evelo Biosciences has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$10.1333Recent Track RecordLast ReportedQ3 2023Last Quarter EPS-$0.66 (Beat by +$0.68)EPS Beat Rate7 of last 8 quartersPrepare for the Earnings CallCompany ProfileQ3 2023 Earnings ReportQ2 2023 Earnings ReportQ1 2023 Earnings Report Evelo Biosciences Earnings FAQ When does Evelo Biosciences report earnings? Evelo Biosciences (NASDAQ:EVLO) is estimated to report earnings on Tuesday, November 17, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Evelo Biosciences? Analysts expect Evelo Biosciences to post earnings of -$10.1333 per share for the quarter. Evelo Biosciences Earnings HeadlinesEvelo Biosciences Inc.June 24, 2026 | marketwatch.comEvelo BiosciencesApril 5, 2026 | fool.comINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as January 27 and has put together a free presentation explaining what is happening inside and why the timing matters.October 27 at 1:00 AM | Paradigm Press (Ad)Evelo Biosciences (OTC:EVLO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comEvelo Biosciences (OTC:EVLO) Stock, Insider Trading ActivityOctober 4, 2024 | benzinga.comEVLO Expands Portfolio with Launch of EVLO SYNERGY - A High-Density 5 MWh Battery Storage SolutionAugust 30, 2024 | ca.finance.yahoo.comSee More Evelo Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Evelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evelo Biosciences and other key companies, straight to your email. Email Address About Evelo BiosciencesEvelo Biosciences (NASDAQ:EVLO) was a clinical-stage biotechnology company focused on developing orally administered medicines designed to act on the small intestine and influence systemic immune responses. Its approach, known as the SINTAX platform, was intended to use selected microbes or microbial-derived signals to modulate immune activity without requiring traditional systemic drug delivery. The company’s development programs targeted inflammatory and immune-mediated diseases, as well as oncology indications. Its lead candidates included EDP1815, an investigational therapy studied in conditions such as psoriasis and atopic dermatitis, and EDP2939, an investigational program designed to stimulate immune responses for potential use in cancer treatment. Evelo was headquartered in Cambridge, Massachusetts, and conducted clinical development activities through research and trial networks in the United States and other regions. In 2023, the company announced that it was discontinuing clinical development activities, reducing its workforce and evaluating strategic alternatives. As a result, Evelo Biosciences is best understood as a former clinical-stage biotechnology company rather than an active developer with a broad commercial product portfolio.View Evelo Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Analysts Turn Bullish on Meta Platforms Despite Post-Earnings FallLockheed Martin's F-35 Deal Could Change How Wall Street Values the StockIntel's $155 Price Target Raises a Bigger Question About Its Turnaround PotentialMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid?Approaching Earnings Season, Are Pure Play Quantum Stocks Still a Good Bet?GXO Logistics Is Turning Warehouse Robots Into a Growth StrategyAnthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants Upcoming Earnings T-Mobile US (10/28/2026)Alphabet (10/28/2026)Alphabet (10/28/2026)Carvana (10/28/2026)eBay (10/28/2026)Garmin (10/28/2026)O'Reilly Automotive (10/28/2026)Equinor ASA (10/28/2026)Phillips 66 (10/28/2026)AON (10/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
